You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Algeta wins FDA approval for prostate cancer treatment

Norwegian drug maker Algeta ASA, which set up a US commercial office in Cambridge’s Kendall Square in September, won Food and Drug Administration approval Wednesday to sell a new treatment for prostate cancer that has spread to the bones.

Algeta’s drug, called Xofigo, treats castration-resistant prostate cancer, a disease that afflicts tens of thousands of men in the United States and many more worldwide. The drug works by releasing targeted alpha-particle-emitting radiation into the bones, killing cancer cells but doing limited damage to surrounding healthy tissue, extending patients’ lives.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week